Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
Violaine Guérin, Pierre Lévy, Jean-Louis Thomas, Thierry Lardenois, Philippe Lacrosse, Emmanuel Sarrazin, Natacha Regensberg-de Andreis, Martine Wonner
Asian Journal of Medicine and Health · pp. 45–55 · Published 15 Jul 2020
10.9734/ajmah/2020/v18i730224Abstract
Aims: The challenge regarding COVID-19 is to prevent complications and fatal evolution. Azithromycin (AZM) and hydroxychloroquine (HCQ) have proven their antiviral effect in vitro. We aimed to assess the efficacy and safety of AZM alone or combined to HCQ, prescribed, at an early stage, in patients with Covid-19, in a primary care setting. Study Design: Retrospective observational study. Place and Duration of Study: Patients have been followed by private practitioners in France, between March and April 2020. Methodology: Eighty-eight patients received either no or a symptomatic treatment (NST) (n=34) or AZM alone (n=34) or AZM+HCQ (n=20). The efficacy end point was the time to clinical recovery and the safety end point was the occurrence of cardiovascular events. To improve the evidence level, a case-control analysis was performed on a sample of 57 patients (19/group) matched for age, sex and BMI. Results: The mean (SD) times to achieve clinical recovery were respectively 25.8 days (11.1), 12.9 days (13.4) and 9.2 days (9.3), showing a statistically significant difference between NST and AZM alone (p<0.0001) or AZM+HCQ (p<0.0001). The statistical difference between NST and AZM was confirmed (p=0.0149) as well as the difference with AZM+HCQ (p=0.0002). No cardiac toxicity was recorded in any patient. No statistical difference was shown between AZM and AZM+HCQ groups, although the dual therapy tended to be more effective in patients over 50 years, based on an analysis using the cox model. Conclusion: AZM and AZM+HCQ favourably impacted the course of the disease. We need trials, ideally prospective/double blind, to show if a statistical difference can be evidenced with a broader group, and clarify the indications of each treatment depending on initial clinical presentation.
Cited by 20
Alberto Boretti · Asian Journal of Chemistry · 2021
Thibault Fiolet, Anthony Guihur, Mathieu Edouard Rebeaud · Clinical Microbiology and Infection · 2021
C. Prodromos, T. Rumschlag · New Microbes and New Infections · 2020
Percy Soto-Becerra, Carlos Culquichicón, Yamilee Hurtado-Roca · 2020
Andrew Ip, Jaeil Ahn, Yizhao Zhou · 2020
Daniel Echeverría-Esnal, Clara Martin-Ontiyuelo, María Eugenia Navarrete-Rouco · Expert Review of Anti-infective Therapy · 2020
Philippe Gautret, Matthieu Million, Pierre-André Jarrot · Expert Review of Clinical Immunology · 2020
Georgia G. Kournoutou, George Dinos · Antibiotics · 2022
Andrew Ip, Jaeil Ahn, Yizhao Zhou · BMC Infectious Diseases · 2021
Roberto Alfonso Accinelli, Grisel Jesús Ynga-Meléndez, Juan Alonso León-Abarca · Travel Medicine and Infectious Disease · 2021
Related research
- Covid-2019:“A Microbiological Monster” — shares topic coverage
- COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
- Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
- Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia — shares topic coverage
- A Review on Intranasal Covid Vaccines for SARS-CoV-2 — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
20
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.